Kiora's KIO-300 suppresses seizure activity in preclinical epilepsy model

Kiora Pharmaceuticals announced preclinical data showing KIO-300 significantly reduced seizure-associated activity in a temporal lobe epilepsy model, suggesting therapeutic potential beyond its current ophthalmology focus. The findings could expand the company's ion channel modulator platform into neurology, potentially opening new revenue opportunities and development pathways.